© 2020 MJH Life Sciences and HCPLive. All rights reserved.
© 2020 MJH Life Sciences™ and HCPLive. All rights reserved.
June 01, 2015
Up to 90 percent of patients with multiple sclerosis have spinal cord pathology.
Experimental stem cell therapy using a patient's own stem cells could offer long-term relief for many patients with multiple sclerosis, though questions still remain regarding cost, patient selection, and efficacy.
May 31, 2015
Research on spinal cord gray matter atrophy in terms of progressive multiple sclerosis has found the highest correlations between disability and gray matter volume loss within the spinal cord.
May 30, 2015
Alemtuzumab has been shown in clinical trials to be more effective than treatment with interferon beta-1a for patients with relapsing-remitting multiple sclerosis. However, the drug's side effect profile requires careful treatment monitoring and follow up.